BFEC
VRCA icon

Benjamin F. Edwards & Company’s Verrica Pharmaceuticals VRCA Stock Holding History

Benjamin F. Edwards & Company’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$3K – 1838
2023
Q2 		$3K Hold
50
– – ﹤0.01% 1648
2023
Q1 		$3K Hold
50
– – ﹤0.01% 1653
2022
Q4 		$1K Hold
50
– – ﹤0.01% 1815
2022
Q3 		$1K Hold
50
– – ﹤0.01% 1790
2022
Q2 		$1K Buy
+50
New +$2.51K ﹤0.01% 1781
2021
Q4 		– Sell
-50
Closed -$6K – 1772
2021
Q3 		$6K Buy
+50
New +$5.61K ﹤0.01% 1500

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Benjamin F. Edwards & Company's VRCA Position: Q3 2023 in Review

Benjamin F. Edwards & Company sold out of Verrica Pharmaceuticals (VRCA) in Q3 2023, closing a stake of 50 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in VRCA in Q3 2021 and held it in 6 quarters. The position peaked at $6K in Q3 2021. 67 funds tracked by Wall St. Rank hold VRCA as of Q3 2023.

  • Benjamin F. Edwards & Company reported no remaining Verrica Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 50 Verrica Pharmaceuticals shares in Q3 2023, an estimated $3K.
  • Benjamin F. Edwards & Company first reported a position in Verrica Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Benjamin F. Edwards & Company's Verrica Pharmaceuticals position peaked at $6K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2023, filed 13 Nov 2023.